Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues
Veru Inc.May 12, 2021 GMT First Patient to Be Enrolled this Week in Phase 3 Clinical Trial of Sabizabulin
(VERU-111) in High Risk Hospitalized COVID-19 Patients New Drug Application Accepted for Review by FDA for Proprietary TADFIN Daily Oral Dosing Combination for BPH; PDUFA Date December 2021 Company Poised to Enroll First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin for Metastatic Castration and AR Targeting Agent Resistant Prostate Cancer Later this Month